- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03901170
Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle? (IVF/ICSI)
Does Use of Letrozole in Controlled Ovarian Stimulation in Normal Ovarian Responder in Fresh Embryo Transfer IVF/ICSI Cycle Improve the Pregnancy Rate?
Letrozole (Femara), is an aromatase inhibitor which is used in the treatment of hormonally-responsive breast cancer after surgery. It is a good target for selective inhibition because estrogen production is a terminal step in the biosynthetic sequence.
Aromatase inhibitors are widely used as adjuvant endocrine therapy for postmenopausal women with breast cancer. They have been used off-label in the treatment of patients for increasing the number of ovarian follicles recruited in ovulatory women undergoing controlled ovarian hyperstimulation (COH). A shorter half-life (48 hours) which would predict a lower risk of teratogenicity. No direct antiestrogenic adverse effects on the endometrium, due to an absence of peripheral estrogen receptor blockade and the shorter half-life.
For ovarian normal responders, instead of hCG (human chorionic gonadotropin), luteal support with exogenous progesterone supplementation is the standard protocol for patients who received fresh embryo transfer for avoiding the risk of OHSS. In other normal responders who have increasing risk of OHSS, the strategy of freezing all embryos are more favored.
In previous studies, high estrogen-induced endometrial gland cells apoptosis might account for the defective endometrial receptivity in women with excessively high estrogen concentrations after ovarian hyperstimulation in IVF cycles. Since letrozole can reduce the serum level of estrogen due to its pharmacological properties, which in turn reduces the adverse effects of high estrogen on the endometrium and improve the endometrial receptivity for embryo implantation.
The investigators anticipate that infertility patients will receive short-term oral administration of letrozole (2.5 mg/tab) once a day when estrogen is elevated in the late stage of ovulation stimulation when receiving ovulation stimulation for two to three days. And transvaginal ultrasound was performed every two to three days for growth of ovarian follicles until two days before oocyte retrieval. Observing whether taking the drug can improve the maturity of the oocyte, pregnancy rate, implantation rate, miscarriage rate, ongoing pregnancy rate and live birth rate of the fresh embryo transfer cycle.
Study Overview
Status
Intervention / Treatment
Detailed Description
Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor which is used in the treatment of hormonally-responsive breast cancer after surgery. Aromatase is a microsomal cytochrome P450 hemoprotein-containing enzyme that catalyzes the rate-limiting step in the production of estrogens: the conversion of androstenedione and testosterone via three hydroxylation steps to estrone and estradiol, respectively. It is a good target for selective inhibition because estrogen production is a terminal step in the biosynthetic sequence. Aromatase activity is present in many tissues, including the ovaries, brain, adipose tissue, muscle, liver, and breast. The investigators use letrozole as routine for patients of breast cancer who want to keep chance of fertility in the future before receiving chemotherapy which may do damage to their ovarian function. After they complete the treatment protocol of breast cancer, they can practice the fertility plan with these frozen embryos or oocytes.
Aromatase inhibitors are widely used as adjuvant endocrine therapy for postmenopausal women with breast cancer. They have been used off-label in the treatment of patients for increasing the number of ovarian follicles recruited in ovulatory women undergoing controlled ovarian hyperstimulation (COH).
A shorter half-life (48 hours) which would predict a lower risk of teratogenicity. No direct antiestrogenic adverse effects on the endometrium, due to an absence of peripheral estrogen receptor blockade and the shorter half-life. In a previous report, the addition of letrozole to gonadotropins (compared with gonadotropins alone) during IVF resulted in a greater number of oocytes and blastocysts, similar pregnancy rates, and no increased risk of ovarian hyperstimulation syndrome.
According to the current guidelines for the treatment course of IVF in NTUH (National Taiwan University Hospital), fresh embryo transfer (ET) cycle is considered for patients who have poor ovarian response because of its low risk of ovarian hyperstimulation syndrome (OHSS). Patients who have high response to ovarian stimulation with freezing all the embryos should be the best policy for avoiding high risk of OHSS and have the advantage of increasing the cumulative pregnancy rate. For ovarian normal responders, instead of hCG, luteal support with exogenous progesterone supplementation is the standard protocol for patients who received fresh embryo transfer for avoiding the risk of OHSS. In other normal responders who have increasing risk of OHSS, the strategy of freezing all embryos are more favored.
In a prospective study had shown that in the population of ovarian normal responder, the cryopreservation group has a higher clinical pregnancy rate per ET transfer (84% vs 54.7%) compared to fresh ET group. The implantation rates were 70.8% and 38.9%, respectively. The ongoing pregnancy rates per transfer (at 10 weeks' gestation) were 78.0% and 50.9%, respectively. The attributable risk percentage of implantation failure due to reduced endometrial receptivity in the fresh group was 64.7%.
The estrogen serum level is about 200~300pg/mL in a normal menstrual period. In previous studies, high estrogen-induced endometrial gland cells apoptosis might account for the defective endometrial receptivity in women with excessively high estrogen concentrations after ovarian hyperstimulation in IVF cycles. Since letrozole can reduce the serum level of estrogen due to its pharmacological properties, which in turn reduces the adverse effects of high estrogen on the endometrium and improve the endometrial receptivity for embryo implantation.
In IVF cycles, the data regarding coadministration of gonadotropins and letrozole for 5 days (days 2-6 or 3-7) in normal and high responders are quite limited. Favorable outcomes related to letrozole have been reported, including lower doses of gonadotropin consumed which decreased the cost of the IVF and increased the number of oocytes and mature oocytes while achieving the same pregnancy rate compared with conventional stimulation.
The investigators anticipate that infertility patients will receive short-term oral administration of letrozole (2.5 mg/tab) once a day when estrogen is elevated in the late stage when receiving ovulation stimulation for two to three days. Other follow-up examinations and general IVF treatments are exactly the same with control group, that is, the whole course of treatment takes about two to three days. Blood test is taken four to five times to check the concentration of hormones: including estrogen, luteinizing hormone, follicle stimulating hormone, progesterone, etc. (about 5 cc each time) And transvaginal ultrasound was performed every two to three days for growth of ovarian follicles until two days before oocyte retrieval. Observing whether taking the drug can improve the maturity of the oocyte, pregnancy rate, implantation rate, miscarriage rate, ongoing pregnancy rate and live birth rate of the fresh embryo transfer cycle.
The first endpoint of our study was to demonstrate higher implantation rates, pregnancy rates, ongoing pregnancy rates and live birth rates in the group of using letrozole. The second endpoint: the investigators want to discover the cut-off value for upper limit of estrogen serum level in fresh ET cycle which does not make significant difference in pregnancy rate between natural estrogen level and in letrozole cycle.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women aged from 20 to 45 years old
- Receive IVF treatment due to infertility
- Plan to have fresh embryo transfer
- Total ovarian follicle number from 8 to 15 before oocyte retrieval
- Plan to have letrozole in IVF treatment routine
Exclusion Criteria:
- Systemic disease, such as diabetes mellitus, hypertension, heart disease, hypothyroidism, liver or renal disease, cancer, autoimmune disease, etc.
- Treatment cycle with pre-implantation genetic screening (PGS)/ pre-implantation genetic diagnosis(PGD)
- Oocyte recipient
- Poor ovarian responders according to Bologna criteria
- Patients who have risk of Ovarian Hyperstimulation Syndrome (OHSS)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: letrozole
patients with letrozole
|
oral administration of letrozole 2.5mg/tab, 1tab once per day from stimulation Day 7 to hCG Day.
|
No Intervention: control
patients without letrozole
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pregnancy rate
Time Frame: 16 days after oocyte retrieval
|
16 days after oocyte retrieval
|
|
implantation rate
Time Frame: 23 days after oocyte retrieval
|
intra-uterine gestational sac/total transfer embryo number
|
23 days after oocyte retrieval
|
miscarriage rate
Time Frame: gestational weeks 12
|
pregnancy loss before gestational weeks 12
|
gestational weeks 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
live birth rate
Time Frame: from gestational weeks 24 to 42
|
live birth with newborn
|
from gestational weeks 24 to 42
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cumulative pregnancy rate
Time Frame: within three months after failure to achieve pregnancy in fresh embryo transfer cycle
|
The sequential frozen-thaw embryo transfer cycle if the patient fail at fresh embryo transfer cycle
|
within three months after failure to achieve pregnancy in fresh embryo transfer cycle
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C, Thomas S. Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed embryo transfer in normal responders. Fertil Steril. 2011 Aug;96(2):344-8. doi: 10.1016/j.fertnstert.2011.05.050. Epub 2011 Jul 6.
- Kyrou D, Popovic-Todorovic B, Fatemi HM, Bourgain C, Haentjens P, Van Landuyt L, Devroey P. Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec-FSH/GnRH antagonist? Hum Reprod. 2009 Nov;24(11):2902-9. doi: 10.1093/humrep/dep290. Epub 2009 Aug 11.
- Chen SU, Chou CH, Chen MJ, Chen TH, Yang YS, Yang JH. Apoptotic effects of high estradiol concentrations on endometrial glandular cells. J Clin Endocrinol Metab. 2014 Jun;99(6):E971-80. doi: 10.1210/jc.2013-3794. Epub 2014 Feb 19.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201810102MINC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Reproductive Techniques, Assisted
-
Merck KGaA, Darmstadt, GermanyMerck Serono GmbH, Germany; Merck B.V., Netherlands; Merck A.E., Greece; Merck... and other collaboratorsCompletedAssisted Reproductive Techniques | Reproductive Technology, AssistedItaly, Russian Federation, United Kingdom, Germany, Poland, Finland, Slovakia, Netherlands, Denmark, France, Greece
-
SEID S.A.RecruitingReproductive Techniques, AssistedSpain
-
Assistance Publique Hopitaux De MarseilleUnknownAssisted Reproductive TechniquesFrance
-
Sykehuset TelemarkCompletedReproductive Techniques, AssistedNorway
-
Tu Du HospitalFederico II University; University of Medicine and Pharmacy at Ho Chi Minh...Recruiting
-
Royan InstituteCompletedAssisted Reproductive TechniquesIran, Islamic Republic of
-
Instituto BernabeuUnknownReproductive Techniques, AssistedSpain
-
IVI BarcelonaCompletedReproductive Techniques, AssistedSpain
-
Instituto BernabeuUnknownReproductive Techniques, AssistedSpain
-
Cairo UniversityCompletedReproductive Techniques, Assisted
Clinical Trials on Letrozole 2.5mg
-
Fudan UniversityRecruitingEndometrial CancerChina
-
Novartis PharmaceuticalsCompletedBreast NeoplasmUnited States, Germany, Spain, United Kingdom, France, Austria, Russian Federation, Italy, Canada, Belgium
-
Mansoura University HospitalCompleted
-
Dartmouth-Hitchcock Medical CenterRecruitingBreast Cancer | ER Positive Breast CancerUnited States
-
Swiss GO Trial GroupHoffmann-La Roche; Novartis Pharmaceuticals; AGO Study Group; Anticancer Fund,... and other collaboratorsRecruitingFallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasm Epithelial | High-grade Serous Ovarian Carcinoma (HGSOC) | Low-grade Serous Ovarian Carcinoma (LGSOC) | Ovarian Endometrioid CarcinomaAustria, Switzerland, Germany
-
EQRx International, Inc.GOG Foundation; European Network of Gynaecological Oncological Trial Groups...Withdrawn
-
Menoufia UniversityRecruitingOvarian StimulationEgypt
-
Cairo UniversityUnknownMedical; Abortion, Fetus
-
University of California, San FranciscoEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingLeiomyoma | Fibroid | Fibroid Uterus | Leiomyoma, UterineUnited States